What would it be like to live in a world where most medical professionals were open to the idea of the legalization of psilocybe assisted therapy, not just the most open-minded or “fringe” among them? Well, mushroom therapy is real and yes there are specials doctors for special therapy that use mushroom treatment protocols.
Even a few short years ago, that notion that special mushroom therapy, special counseling, or using special medicine for therapy, treatments, and counseling would have seemed extraordinary, bordering on the impossible, but recent developments in loosening legal frameworks, overall societal acceptance, and, perhaps most influential, a staggering amount of interest from both public and private researchers may result in far more psilocybe-friendly medical professionals than even the most ardent of advocates could have ever asked for.
Psychedelic therapy being delivered in psychotherapy centers is real and is being used in conjunction with specials counseling for anxiety and depression, PTSD, and for other medical health issues such as mushrooms for emotional wellness.
As a number of US states consider legalizing psilocybe therapy and decide to examine the benefits of psilocybe-assisted therapy and doctors themselves come out about palliative care experiences in their practices, and about their own special experiences using the most potent psilocybe cubensis strains for therapeutically valid purposes, the special mushroom therapy benefits list continues to grow. The collective ears and research departments of the private pharmaceuticals, research, and medical sectors have started to perk up as we covered in our post about the specials industry and psilocybe industry companies.
One such organization is Braxia Scientific, which recently announced the launch of a clinical training program designed to educate physicians, psychotherapists, and psychologists in psilocybe-assisted therapy.
Braxia Scientific to Launch Clinical Training Program for Medical Professionals Focusing on Psilocybe-Assisted Therapy
While we typically cover psilocybe related news within the United States, The Toronto-based Braxia Scientific’s program is taking place in Canada.
Here’s why it’s still noteworthy for us Yankees: if the program and others like it succeed, it’s likely that this influence will trickle down to the United States—which, if you weren’t aware, actually does play host to several clinical training organizations who concentrate on the therapeutic application of specials. One example of a clinic concentrating on the therapeutic specials includes the Multidisciplinary Association for Psychedelic Studies. However, we’re not aware of any that focus on psilocybe mushroom treatments or special mushroom therapy specifically by their doctors or medical professionals.
Thus, it’s worth noting that perhaps the most interesting facet of Braxia’s training program is the fact that it does specifically focus on psilocybe-based treatments; there are other clinical training programs with similar intentions but they’re either broader in scope, focusing on specials as a whole, or focused on a different compound, such as MDMA or ketamine. There are even stories about mushrooms and Christmas celebrations.
We are encouraged to see the growing number of clinical studies focused on demonstrating that psilocybe, and other potential specials, may be safe and effective in treating people with multiple mental health conditions including treatment-resistant depression.
Roger McIntyre, CEO, Braxia Scientific
Braxia’s program will train physicians and other medical professionals in how to best administer psilocybe to patients with depression. This is a relatively new area of study—at least in terms of western medicine—but there is plenty of evidence which strongly suggests that psilocybe is an effective tool, particularly for those patients who have “tried everything else.”
This includes those men having reproductive problems in their life that want to try penis envy mushrooms spores therapy for their particular health issues.
As far as medical depression and anxiety is concerned, the mushroom benefits of psilocybe compounds likely have something to do with psilocybe’s ability to “rewire” the brain by promoting new synaptic connections. Once new neural pathways are formed, important neurotransmitters like serotonin, the substance responsible for feelings of happiness and well-being, will actually have an easier time traveling throughout the brain. It’s an impossibly complex topic that is admittedly well over the head of this author, but we did do a fairly decent job of explaining how all this works (at a basic level) in The Psilocybe Philosophy post Neuroplasticity Explained: Can Psilocybe Rewire the Brain?.
Braxia’s program, and likely others similar to it, will teach trainees not only how to properly dose psilocybe, but to help the patient process the experience. Once trained, medical professionals can participate in future clinical trials for psilocybe assisted therapy. In the future, it’s probable that their training could be applied clinically, assuming psilocybe legislation keeps moving in a permissive direction (as it currently is in both Canada and the United States).
Will There Be More Psilocybe-Based Clinical Training Programs? And Will They Come to The United States?
At this point, it’s almost a certainty that there will be clinical training programs and special clinical trials conducted specifically for psilocybe-based treatments in the United States. At the time of this writing they’re few and far between, but that’s likely to change if the steadily increasing number us United States individual states jurisdictions continue to examine the possibility of legalizing psilocybe (for regulated therapeutic use if not outright).
An ongoing court case that could be a major stepping stone to this end might end up being the lawsuit against the United States Drug Enforcement Agency by Dr. Sunil Aggarwal and a slew of cancer patients and state attorneys. The doctor and his cohort are seeking approval for access to psilocybe for end-of-life patients on the basis of the federal Right To Try law.
Only time will tell, but for psilocybe advocates, things are looking good.
Braxia’s Program Focuses on Psilocybe as a Treatment for Depression, But Can Psilocybe Do More?
Most clinical studies or training programs concentrate on the use of psilocybe to treat depression. However, evidence continues to strongly suggest that the compound can be an effective treatment to realize the benefits of mushrooms therapy, from PTSD to obesity to lesser-studied ailments like psilocybe for tinnitus therapy.
Calling All Amateur Microscopists: Study Psilocybe Mushroom Spores At Home, Legally For Mushroom Therapy
Did you know that there’s another group of passionate researchers dedicated to studying the formative stages of the fungi that brings us psilocybe?
It’s true! Amateur microscopists and mycologists from around the country are legally studying psilocybe mushroom spore after questioning are mushroom spores legal in my state? Since spores contain no psilocybe, as long as researchers never cultivate them in jurisdictions where doing so is disallowed, they’re perfectly fine to possess and use for personal mushroom therapy purposes.
There are perfectly legitimate reasons medical doctors are using specials for depression, therapy, mental health, tinnitus, PTSD, and for special counseling purposes in psychotherapy centers.
Quality Spores Offers More Ways to Pay
Given our product, although legal in 47 states, we sometimes experience interruptions with our credit card processors. So, as a service to our loyal customers, we also accept other forms of payments including cryptocurrencies, Zelle and Venmo.
We never want you to miss an opportunity to expand your collection of spores, or miss out on discovering something new in your research. And to that end we wrote informative guides on setting up these other forms of payments and show you how easy they are to use. So don’t miss out, always be prepared to keep your studies moving forward.